Rethinking Collaboration in Biologics Discovery

Supported by:

4 May 2017

Supported by:

4 May 2017

Today’s biotherapeutics research labs need to be able to successfully work with big data (genomics), public data, and various classes of experimental data to effectively operate in the modern world of biologics R&D. This environment only becomes more complex as many organisations are exploring external partnerships to leverage new sources of innovation.

However, often not all of this data and associated meta-data is readily available to a project team as legacy systems and processes make sharing data across these collaborative networks prohibitively inefficient. As a result, they are forced to make decisions without all of the information available to them, which can significantly hinder the quality and speed of biotherapeutic development.

In this webinar, we illustrated how BIOVIA can help to improve the collaboration between internal and external scientists.

What attendees learnt during this webinar:

• The increasingly complex networks and repositories of data available to biologics researchers
• How to more successfully manage collaboration across internal and external research teams
• Case Study: The value of the interaction of real time predictive models, genomics data, and assay data in biologics research

Keynote speaker

Dr. Anne Goupil, Principal Field Application Scientist, Dassault Systèmes BIOVIA

Anne Goupil-Lamy, Ph.D., principal field application scientist and Science Council Fellow at BIOVIA, obtained her doctorate in molecular biophysics from the University of Pierre and Marie Curie (Paris VI, France). She studied protein dynamics and denaturation using molecular dynamic simulations and neutron scattering experiments under the supervision of Professor Jeremy C. Smith.

Goupil-Lamy joined MSI (now BIOVIA) in 1998 as a support scientist and gained expertise in the many modelling areas supported by BIOVIA’ life science modelling tools. While managing BIOVIA’ contract research group for many years in Europe and worldwide, she performed feasibility studies, developed proposals and was involved in the delivery of structure-based design and ligand-based design projects with one contract resulting in a patent.

As a pre-sales scientist, she has performed several validation studies in fragment-based design and protein-protein interactions that were presented at conferences and to customers. She is also involved in biotherapeutics projects focusing on antibody design.

Supported by Dassault Systèmes BIOVIA

Dassault Systèmes BIOVIA focuses on scientific collaborative environments for advanced biological, chemical and materials experiences. The sophisticated enterprise system of modeling, simulation, laboratory and quality management enables innovation for science-based industries. The BIOVIA experience sets new software standards for life science and process-based industry enterprises to discover, design, deploy and deliver innovative, sustainable, and competitive products of higher quality to consumers globally. 
Find out more: www.3ds.com